PTPI — Petros Pharmaceuticals Share Price
Last trade - 00:00- $3.35m
- $6.71m
- $5.82m
- 46
- 55
- 16
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.08 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -167.09% | ||
| Return on Equity | -390.17% | ||
| Operating Margin | -337.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.58 | 9.56 | 7.81 | 5.99 | 5.82 | 5.43 | 5.47 | -16.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- May 14th, 2020
- Public Since
- December 2nd, 2020
- No. of Shareholders
- 297
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,014,872
- Address
- 1185 Avenue Of The Americas, NEW YORK, 10036
- Web
- https://www.petrospharma.com/
- Phone
- +1 9732420005
- Auditors
- EisnerAmper LLP
Upcoming Events for PTPI
Similar to PTPI
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Achilles Therapeutics
NASDAQ Capital Market
FAQ
As of Today at 21:37 UTC, shares in Petros Pharmaceuticals are trading at $0.34. This share price information is delayed by 15 minutes.
Shares in Petros Pharmaceuticals last closed at $0.34 and the price had moved by -74.43% over the past 365 days. In terms of relative price strength the Petros Pharmaceuticals share price has underperformed the S&P500 Index by -80.67% over the past year.
The overall consensus recommendation for Petros Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePetros Pharmaceuticals does not currently pay a dividend.
Petros Pharmaceuticals does not currently pay a dividend.
Petros Pharmaceuticals does not currently pay a dividend.
To buy shares in Petros Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.34, shares in Petros Pharmaceuticals had a market capitalisation of $3.35m.
Here are the trading details for Petros Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PTPI
Based on an overall assessment of its quality, value and momentum Petros Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Petros Pharmaceuticals is $1.00. That is 198.51% above the last closing price of $0.34.
Analysts covering Petros Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Petros Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -38.82%.
As of the last closing price of $0.34, shares in Petros Pharmaceuticals were trading -43.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Petros Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Petros Pharmaceuticals' directors